Research Progress of Biomarkers for Immune Checkpoint Inhibitors on Digestive System Cancers

• Published in: Frontiers in immunology Vol. 13; p. 810539
• Main Authors: Wang, Jingting, Ma, Xiao, Ma, Zhongjun, Ma, Yan, Wang, Jing, Cao, Bangwei
• Format: Journal Article
• Language: English
• Published: Switzerland Frontiers Media S.A 13.04.2022
• Subjects: biomarker; Biomarkers, Tumor - metabolism; digestive system cancers; Digestive System Neoplasms - drug therapy; DNA Mismatch Repair; Humans; immune check inhibitor (ICI); Immune Checkpoint Inhibitors - therapeutic use; Immunologic Factors - therapeutic use; Immunology; Immunotherapy; predict therapeutic effectiveness; immune check inhibitor (ICI); digestive system cancers; biomarker; immunotherapy; predict therapeutic effectiveness
• ISSN: 1664-3224; 1664-3224
• DOI: 10.3389/fimmu.2022.810539

Immunotherapy represented by immune checkpoint inhibitors has gradually entered a new era of precision medicine. In view of the limited clinical benefits of immunotherapy in patients with digestive system cancers, as well as the side-effects and high treatment costs, development of biomarkers to predict the efficacy of immune therapy is a key imperative. In this article, we review the available evidence of the value of microsatellite mismatch repair, tumor mutation burden, specific mutated genes or pathways, PD-L1 expression, immune-related adverse reactions, blood biomarkers, and patient-related biomarkers in predicting the efficacy of immunotherapy against digestive system cancers. Establishment of dynamic personalized prediction models based on multiple biomarkers is a promising area for future research.